arrow_back Back to App

Increased Transparency of Drug Research and Manufacturing Costs

New regulations aim to increase the transparency of drug clinical trial costs and pharmaceutical companies' research and development expenditures. This will give citizens access to information on how much it costs to develop a drug, potentially influencing discussions about drug prices and accessibility.
Key points
Companies conducting drug clinical trials will be required to publicly disclose detailed cost data for these trials, including per-patient costs and expenditures on personnel or materials.
Drug manufacturers will be obligated to report their total research and development expenditures, broken down by stages, from basic research to post-market studies.
This information will be available on dedicated websites, making it easier for citizens to understand how drug prices are determined.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_4037
Sponsor: Sen. Stabenow, Debbie [D-MI]
Process start date: 2022-04-07
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pharmaceutical Research Transparency Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_4037.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-04-07.

What are the main provisions?

Key points include:

  • Companies conducting drug clinical trials will be required to publicly disclose detailed cost data for these trials, including per-patient costs and expenditures on personnel or materials.
  • Drug manufacturers will be obligated to report their total research and development expenditures, broken down by stages, from basic research to post-market studies.
  • This information will be available on dedicated websites, making it easier for citizens to understand how drug prices are determined.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Stabenow, Debbie [D-MI].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health Economy